Novartis AG
NVS
$112.71
$0.830.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.14% | 8.84% | 9.40% | 9.55% | 8.01% |
| Total Other Revenue | 14.73% | 12.58% | 16.88% | 16.87% | -9.49% |
| Total Revenue | 15.13% | 8.93% | 9.60% | 9.71% | 7.39% |
| Cost of Revenue | 28.95% | 3.98% | -5.18% | 3.34% | -6.75% |
| Gross Profit | 11.28% | 10.65% | 15.47% | 12.08% | 12.13% |
| SG&A Expenses | 2.49% | 1.33% | -0.03% | -1.76% | 9.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 123.43% | -97.27% | -107.37% | -56.21% | 62.09% |
| Total Operating Expenses | 66.21% | -15.95% | -2.94% | -6.40% | -6.27% |
| Operating Income | -33.03% | 164.65% | 47.61% | 79.07% | 24.48% |
| Income Before Tax | 38.20% | 118.11% | 43.64% | 24.17% | 51.50% |
| Income Tax Expenses | 278.16% | 412.82% | 47.64% | 19.19% | -202.76% |
| Earnings from Continuing Operations | 6.90% | 110.51% | 42.93% | 25.02% | 100.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 3,768.87% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 300.00% | -- | -- | -- |
| Net Income | -66.77% | 81.09% | 40.16% | 17.23% | 478.44% |
| EBIT | -33.03% | 164.65% | 47.61% | 79.07% | 24.48% |
| EBITDA | -41.81% | 88.62% | 30.39% | 41.98% | 17.56% |
| EPS Basic | -65.72% | 85.60% | 43.60% | 21.02% | 502.92% |
| Normalized Basic EPS | -31.08% | 196.55% | 51.63% | 86.11% | 32.81% |
| EPS Diluted | -65.63% | 84.60% | 43.00% | 21.53% | 498.66% |
| Normalized Diluted EPS | -31.16% | 196.18% | 51.54% | 85.92% | 33.16% |
| Average Basic Shares Outstanding | -3.07% | -2.42% | -2.40% | -3.13% | -4.06% |
| Average Diluted Shares Outstanding | -2.95% | -2.31% | -2.34% | -3.02% | -4.31% |
| Dividend Per Share | -1.44% | -- | -- | -- | 13.24% |
| Payout Ratio | -- | -- | -- | -0.39% | -- |
